SCHEMBL6141546

SCHEMBL6141546

O=C(O)c1ccccc1Nc1cc(Cl)c(Cl)cc1Nc1ccccc1C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.68
MEN1 O00255 5/20 0.66
KMT2A Q03164 5/20 0.66
AKR1C3 P42330 4/20 0.66
TTR P02766 3/20 0.66
PTGS2 P35354 3/20 0.66
ADORA3 P0DMS8 2/20 0.66
MAPT P10636 2/20 0.66
LMNA P02545 2/20 0.66
CYP1A2 P05177 2/20 0.66
CYP3A4 P08684 2/20 0.66
CYP2C9 P11712 2/20 0.66
HIF1A Q16665 2/20 0.66
USP2 O75604 1/20 0.66
MT-CO2 P00403 1/20 0.66
PLA2G1B P04054 1/20 0.66
PGR P06401 1/20 0.66
HTR1A P08908 1/20 0.66
ADRA2A P08913 1/20 0.66
AR P10275 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4249088 0.87 PBRM1 (0.75) PBRM1MEN1KMT2AAKR1C3TTR
SCHEMBL30575470 0.87 PBRM1 (0.75) PBRM1MEN1KMT2AAKR1C3TTR
SCHEMBL30320327 0.86 FABP4 (0.80) PBRM1MEN1KMT2AAKR1C3TTR
SCHEMBL355549 0.86 FABP4 (0.80) PBRM1MEN1KMT2AAKR1C3TTR
SCHEMBL28297347 0.85 PBRM1 (0.73) PBRM1MEN1KMT2AAKR1C3TTR
SCHEMBL6141395 0.85 CLCN2 (0.64) PBRM1MEN1KMT2AAKR1C3TTR
SCHEMBL6140792 0.84 FABP4 (0.62) PBRM1MEN1KMT2AAKR1C3TTR
SCHEMBL6142375 0.84 FABP4 (0.84) PBRM1MEN1KMT2AAKR1C3TTR
SCHEMBL9691899 0.84 FABP4 (0.77) PBRM1MEN1KMT2AAKR1C3TTR
SCHEMBL11106279 0.84 AKR1C3 (0.64) PBRM1MEN1KMT2AAKR1C3TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1525183-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-04-27 EP claimed
US-20040142993-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US claimed
WO-2004002940-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY (US) 2004-01-08 WO claimed
EP-1525183-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-04-27 EP disclosed
US-20040142993-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US disclosed
WO-2004002940-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142993-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 PBRM1 3397/4885MEN1 4847/4885KMT2A 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.